您的当前位置:首页 > 行业数据 > 埃万妥单抗联合化疗一线治疗EGFRex20insNSCLC的全球三期PAPILLON临
图片属性
图片格式:PNG 图片大小:450KB 图片尺寸:2268*789
同报告图片
 / 4
埃万妥单抗联合化疗一线治疗EGFRex20insNSCLC的全球三期PAPILLON临_第1页
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
埃万妥单抗联合化疗一线治疗EGFRex20insNSCLC的全球三期PAPILLON临_第2页
埃万妥单抗联合化疗一线治疗EGFRex20insNSCLC的全球三期PAPILLON临_第3页
埃万妥单抗联合化疗一线治疗EGFRex20insNSCLC的全球三期PAPILLON临_第4页
埃万妥单抗联合化疗一线治疗EGFRex20insNSCLC的全球三期PAPILLON临_第5页
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
所属报告: 创新药疾病行业专题报告:EGFR ex20ins NSCLC处于突破的前夜布局正当时-231115(57页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠